• Daiana Perez Visñuk, Graciela Savoy de Giori, Jean Guy LeBlanc, and de Moreno de LeBlanc Alejandra A Centro de Referencia para Lactobacilos, San Miguel de Tucumán, Tucumán, Argentina. Electronic address: demoreno@cerela.org.ar..
• Centro de Referencia para Lactobacilos, San Miguel de Tucumán, Tucumán, Argentina.
• Nutrition. 2020 Nov 1; 79-80: 110995.

ObjectivesParkinson's disease (PD) is a neurodegenerative process that affects the motor function and involves an inflammatory response and B vitamin deficiencies. The aim of this study was to evaluate the effect of B-group vitamin-producing and immunomodulatory lactic acid bacteria (LAB) in a murine model of PD.MethodsThe effect of Lactobacillus plantarum CRL 2130 (a riboflavin producer), Streptococcus thermophilus CRL 807 (an immunomodulatory strain), and Streptococcus thermophilus CRL 808 (a folate producer) were evaluated individually and as a mixture in mice injected with 1-methyl-4-fenil-1,2,3,6-tetrahidropiridina. Motor capacity, tyrosine hydrolase in the brain, and cytokine concentrations in serum and brain tissues were evaluated in 1-methyl-4-fenil-1,2,3,6-tetrahidropiridina-treated mice after bacterial supplementation.ResultsThe mice receiving the selected LAB showed significantly improved motor skills compared with those that did not receive bacterial supplementation. When given the mixture of all 3 strains together, the animals had higher brain tyrosine hydrolase-positive cell counts, decreased inflammatory cytokines interleukin 6 and tumor necrosis factor alpha in serum, and increased antiinflammatory cytokine interleukin 10 in serum and brain tissues compared with animals that did not receive LAB supplementation.ConclusionsThe results showed the potential of a selected LAB mixture to improve motor behavior and neuroinflammation in PD. This probiotic mixture could be used as an adjunct treatment in the control of PD.Copyright © 2020 Elsevier Inc. All rights reserved.

6 keywords...

hide…